Cannabis reclassification: the beginning of a new era for medicine

For decades, cannabis has occupied a complex place within U.S. legislation. While millions of patients use it for therapeutic purposes and dozens of states have developed medical cannabis programs, at the federal level the plant continued to be treated as a substance with no accepted medical value.

That scenario is changing.

In a recent interview with MJBizDaily , Dr. Chanda Macias , scientist and executive director of the National Holistic Healing Center in Washington, D.C., shared her perspective on what the reclassification of cannabis to Schedule III truly represents. Her message is clear: this change goes far beyond a legal decision; it represents a complete transformation in how the industry will operate.

From dispensary to a more clinical model

For Macias, the future of medicinal cannabis will be much more like the traditional pharmaceutical system.

Dispensaries will need to adopt more rigorous protocols, manufacturing processes will evolve towards pharmaceutical standards, and professionals responsible for caring for patients will need much stronger clinical preparation.

In other words, the conversation will shift from solely focusing on selling products to focusing on offering treatments backed by quality, consistency, and scientific evidence.

Quality will no longer be a competitive advantage… it will be a requirement

One of the most important points of the interview is that many companies still operate under standards developed to comply with state regulations. However, eventual integration into the federal system will require much stricter processes.

Good manufacturing practices (GMP), quality controls, traceability, product stability, scientific documentation, and laboratory validations will go from being differentiating factors to becoming essential requirements to remain in the market.

This also opens up a huge opportunity for laboratories, researchers, and companies that have already committed to developing products with a medical focus and clinical evidence.

More research, more confidence

The reclassification also has scientific implications.

Recognizing an accepted medical use facilitates the development of clinical research and collaboration with academic and pharmaceutical institutions. This could accelerate the arrival of new cannabis-derived medicines with regulatory approval and expand the therapeutic options available to patients.

Although the reclassification does not mean full federal legalization, it does reduce important barriers to studying the plant under more robust scientific standards.

The industry is entering its maturity stage

For years, the growth of cannabis was driven primarily by state regulation and innovation from small operators.

The next stage looks different.

The industry is beginning to move towards an environment where doctors, pharmacists, researchers, manufacturers, and regulatory agencies will share a much more active role in the development of medicinal products.

For many companies, this will mean a significant investment in infrastructure and regulatory compliance. For others, it will be an opportunity to position themselves as leaders in a new generation of medicinal cannabis.

Sens Culture's vision

The possible definitive arrival of cannabis to Schedule III should not be interpreted as the end point of a regulatory struggle, but as the beginning of a new stage.

In the coming years, it is reasonable to expect an increase in clinical research, higher quality standards, closer integration with healthcare systems, and accelerated professionalization across the industry. We will also see the market become more clearly divided between wellness products and medicines developed under pharmaceutical criteria.

The real challenge will no longer be proving that cannabis has therapeutic potential. The challenge will be demonstrating which products offer sufficient evidence to become part of the medicine of the future.

And those who start preparing today will be the ones who lead the next generation of the cannabis industry.